Extent of lymphadenectomy and prognosis after esophageal cancer surgery

JAMA Surgery

Volumn 151, Issue 1, 2016, Pages 32-39

  Lagergren, Jesper ^a,b,c   Mattsson, Fredrik ^c   Zylstra, Janine ^a,b,c   Chang, Fuju ^b   Gossage, James ^a,b,c   Mason, Robert ^a,b,c   Lagergren, Pernilla ^b,c   Davies, Andrew ^a,b,c  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER SURGERY; COHORT ANALYSIS; DISEASE SPECIFIC SURVIVAL; ESOPHAGUS CANCER; ESOPHAGUS SURGERY; HUMAN; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MORTALITY RATE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROSPECTIVE STUDY; SURGICAL MORTALITY; ADENOCARCINOMA; CARCINOMA, SQUAMOUS CELL; ENGLAND; EPIDEMIOLOGY; ESOPHAGEAL NEOPLASMS; ESOPHAGUS RESECTION; FOLLOW UP; LYMPH NODE; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; TUMOR RECURRENCE; VERY ELDERLY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; COHORT STUDIES; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; FOLLOW-UP STUDIES; HUMANS; LONDON; LYMPH NODE EXCISION; LYMPH NODES; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROPORTIONAL HAZARDS MODELS;

EID: 84955247393     PISSN: 21686254     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamasurg.2015.2611     Document Type: Article

References (33)

1. Jemal A, Bray F, Center MM, Ferlay J,Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-90.
2. Lagergren J, Lagergren P. Recent developments in esophageal adenocarcinoma. CA Cancer J Clin. 2013;63(4):232-248.
3. van Hagen P, Hulshof MC, van Lanschot JJ, et al; CROSS Group. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012; 366(22):2074-2084.
4. Rouvelas I, ZengW, Lindblad M, Viklund P, YeW, Lagergren J. Survival after surgery for oesophageal cancer: a population-based study. Lancet Oncol. 2005;6(11):864-870.
5. Wu PC, Posner MC. The role of surgery in the management of oesophageal cancer. Lancet Oncol. 2003;4(8):481-488.
6. Lagarde SM, Vrouenraets BC, Stassen LP, van Lanschot JJ. Evidence-based surgical treatment of esophageal cancer: overview of high-quality studies. Ann Thorac Surg. 2010;89(4):1319-1326.
7. Pennathur A, Gibson MK, Jobe BA, Luketich JD. Oesophageal carcinoma. Lancet. 2013;381(9864): 400-412.
8. Rizk N. Surgery for esophageal cancer: goals of resection and optimizing outcomes. Thorac Surg Clin. 2013;23(4):491-498.
9. Jamieson GG, Lamb PJ, Thompson SK. The role of lymphadenectomy in esophageal cancer. Ann Surg. 2009;250(2):206-209.
10. Allum WH, Blazeby JM, Griffin SM, Cunningham D, Jankowski JA,Wong R; Association of Upper Gastrointestinal Surgeons of Great Britain and Ireland, the British Society of Gastroenterology and the British Association of Surgical Oncology. Guidelines for the management of oesophageal and gastric cancer. Gut. 2011;60(11):1449-1472.
11. van der Schaaf M, Johar A, Wijnhoven B, Lagergren P, Lagergren J. Extent of lymph node removal during esophageal cancer surgery and survival. J Natl Cancer Inst. 2015;107(5):djv043.
12. Davies AR, Gossage JA, Zylstra J, et al. Tumor stage after neoadjuvant chemotherapy determines survival after surgery for adenocarcinoma of the esophagus and esophagogastric junction. J Clin Oncol. 2014;32(27):2983-2990.
13. Davies AR, Sandhu H, Pillai A, et al. Surgical resection strategy and the influence of radicality on outcomes in oesophageal cancer. Br J Surg. 2014; 101(5):511-517.
14. Rice TW, Blackstone EH, Rusch VW. 7th edition of the AJCC Cancer Staging Manual: esophagus and esophagogastric junction. Ann Surg Oncol. 2010;17 (7):1721-1724.
15. Mandard AM, Dalibard F, Mandard JC, et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma: clinicopathologic correlations. Cancer. 1994;73(11):2680-2686.
16. Sobin LH, Gospodarowicz MK, Wittekind C, eds. International Union Against Cancer TNM Classification of Malignant Tumours. 7th ed. Oxford, England: Wiley-Blackwell; 2009.
17. Rizk NP, Ishwaran H, Rice TW, et al. Optimum lymphadenectomy for esophageal cancer. Ann Surg. 2010;251(1):46-50.
18. Little RJA, Rubin DB. Statistical AnalysisWith Missing Data. 2nd ed. Hoboken, NJ:Wiley; 2002.
19. Ye T, Sun Y, Zhang Y, Zhang Y, Chen H. Three-field or two-field resection for thoracic esophageal cancer: ameta-analysis. Ann Thorac Surg. 2013;96(6):1933-1941.
20. Brusselaers N, Mattsson F, Lagergren J. Hospital and surgeon volume in relation to long-term survival after oesophagectomy: systematic review and meta-analysis. Gut. 2014;63 (9):1393-1400.
21. Hulscher JB, van Sandick JW, de Boer AG, et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med. 2002;347(21): 1662-1669.
22. Omloo JM, Lagarde SM, Hulscher JB, et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of themid/distal esophagus: five-year survival of a randomized clinical trial. Ann Surg. 2007;246(6): 992-1000.
23. Boshier PR, Anderson O, Hanna GB. Transthoracic versus transhiatal esophagectomy for the treatment of esophagogastric cancer: ameta-analysis. Ann Surg. 2011;254(6):894-906.
24. Nishihira T, Hirayama K, Mori S. A prospective randomized trial of extended cervical and superior mediastinal lymphadenectomy for carcinoma of the thoracic esophagus. Am J Surg. 1998;175(1): 47-51.
25. Talsma K, van Hagen P, Grotenhuis BA, et al. Comparison of the 6th and 7th Editions of the UICC-AJCC TNM Classification for Esophageal Cancer. Ann Surg Oncol. 2012;19(7):2142-2148.
26. Sanghani M, Balk EM, Cady B. Impact of axillary lymph node dissection on breast cancer outcome in clinically node negative patients: a systematic review and meta-analysis. Cancer. 2009;115(8): 1613-1620.
27. Cormier JN, Askew RL, Mungovan KS, Xing Y, Ross MI, Armer JM. Lymphedema beyond breast cancer: a systematic review and meta-analysis of cancer-related secondary lymphedema. Cancer. 2010;116(22):5138-5149.
28. May K, Bryant A, Dickinson HO, Kehoe S, Morrison J. Lymphadenectomy for the management of endometrial cancer. Cochrane Database Syst Rev. 2010;(1):CD007585.
29. Wright JD, Barrena Medel NI, Sehouli J, Fujiwara K, Herzog TJ. Contemporary management of endometrial cancer. Lancet. 2012;379(9823): 1352-1360.
30. Michalski CW, Kleeff J,Wente MN, Diener MK, Büchler MW, Friess H. Systematic review and meta-analysis of standard and extended lymphadenectomy in pancreaticoduodenectomy for pancreatic cancer. Br J Surg. 2007;94(3): 265-273.
31. Jiang L, Yang KH, Chen Y, et al. Systematic review and meta-analysis of the effectiveness and safety of extended lymphadenectomy in patients with resectable gastric cancer. Br J Surg. 2014;101 (6):595-604.
32. Xu X, Zhang H, Zhou P, Chen L. Meta-analysis of the efficacy of pancreatoduodenectomy with extended lymphadenectomy in the treatment of pancreatic cancer [retracted inWorld J Surg Oncol. 2015;13:125].World J Surg Oncol. 2013;11:311.
33. Georgiou P, Tan E, Gouvas N, et al. Extended lymphadenectomy versus conventional surgery for rectal cancer: ameta-analysis. Lancet Oncol. 2009;10(11):1053-1062.